Figures & data
Figure 1 QuantiTect Primer Assay specification.
![Figure 1 QuantiTect Primer Assay specification.](/cms/asset/ae7b948a-7495-40b4-9eec-4a36b4fb6a95/dddt_a_124102_f0001_c.jpg)
Figure 2 Time- and dose-dependent antiproliferation effect of imatinib mesylate with clinically relevant concentrations (2–10 µM) in two MCF7 and T-47D breast tumorigenic cell lines and a nontumorigenic breast cell line MCF 10A.
![Figure 2 Time- and dose-dependent antiproliferation effect of imatinib mesylate with clinically relevant concentrations (2–10 µM) in two MCF7 and T-47D breast tumorigenic cell lines and a nontumorigenic breast cell line MCF 10A.](/cms/asset/5a2ca991-ea9e-4faa-a4c2-588585e1a575/dddt_a_124102_f0002_c.jpg)
Figure 3 The concentration of imatinib mesylate that is required for 50% inhibition of two MCF7 and T-47D breast tumorigenic cell lines and a nontumorigenic breast cell line MCF 10A proliferation (half minimal inhibitory concentration) after 144 h treatment compared to untreated cell lines.
![Figure 3 The concentration of imatinib mesylate that is required for 50% inhibition of two MCF7 and T-47D breast tumorigenic cell lines and a nontumorigenic breast cell line MCF 10A proliferation (half minimal inhibitory concentration) after 144 h treatment compared to untreated cell lines.](/cms/asset/da9e349a-a9d5-422b-821f-6867e6feed13/dddt_a_124102_f0003_b.jpg)
Figure 4 Apoptosis terminal deoxynucleotidyl transferase dUTP nick end labeling assay detection of time-dependent imatinib mesylate apoptosis induction within 48–144 h treatment with corresponding half minimal inhibitory concentration of imatinib mesylate for each cell line.
![Figure 4 Apoptosis terminal deoxynucleotidyl transferase dUTP nick end labeling assay detection of time-dependent imatinib mesylate apoptosis induction within 48–144 h treatment with corresponding half minimal inhibitory concentration of imatinib mesylate for each cell line.](/cms/asset/fe0c0abd-5621-4907-b1ff-7bfc4de8dfed/dddt_a_124102_f0004_c.jpg)
Figure 5 The effect of imatinib mesylate on cell cycle distribution of MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines.
Abbreviations: G, gap; M, mitosis; S, synthesis; PI-A, propidium iodide-A.
![Figure 5 The effect of imatinib mesylate on cell cycle distribution of MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines.](/cms/asset/78e14121-e8ad-408d-b658-54eaeaf575b2/dddt_a_124102_f0005_c.jpg)
Figure 6 Comparative expression of the PDGFR-β, c-Kit, PDGF-BB and SCF genes compared to house-keeping gene (β-actin) in untreated two MCF7 and T-47D breast tumorigenic cell lines and a nontumorigenic breast cell line MCF 10A.
![Figure 6 Comparative expression of the PDGFR-β, c-Kit, PDGF-BB and SCF genes compared to house-keeping gene (β-actin) in untreated two MCF7 and T-47D breast tumorigenic cell lines and a nontumorigenic breast cell line MCF 10A.](/cms/asset/33d74bf0-1812-42bb-9244-726bfabcc8a5/dddt_a_124102_f0006_c.jpg)
Figure 7 The relative gene expression pattern profiling of the PDGFR-β, c-Kit, PDGF-BB and SCF genes in imatinib mesylate-treated cell lines compared to untreated controls and normalized with HK genes.
Abbreviations: PDGF-BB, platelet-derived growth factor BB; PDGFR, platelet-derived growth factor receptor; SCF, stem cell factor.
![Figure 7 The relative gene expression pattern profiling of the PDGFR-β, c-Kit, PDGF-BB and SCF genes in imatinib mesylate-treated cell lines compared to untreated controls and normalized with HK genes.](/cms/asset/6561da28-7b5c-4901-b238-c668522fa3eb/dddt_a_124102_f0007_c.jpg)
Table 1 The relative gene expression analysis report
Figure 8 Relative expression of the PDGFR-β, c-Kit, PDGF-BB and SCF proteins compared to house-keeping protein (β-actin) in untreated cell lines.
![Figure 8 Relative expression of the PDGFR-β, c-Kit, PDGF-BB and SCF proteins compared to house-keeping protein (β-actin) in untreated cell lines.](/cms/asset/5bef58c2-0d5b-4393-a2e9-2011905e208d/dddt_a_124102_f0008_c.jpg)
Figure 9 The effect of imatinib mesylate treatment on PDGFR-β, c-Kit, PDGF-BB and SCF protein expression related to untreated cell lines.
Abbreviations: PDGF-BB, platelet-derived growth factor BB; PDGFR, platelet-derived growth factor receptor; Tr, treated-cell lines; UnTr, untreated-cell lines.
![Figure 9 The effect of imatinib mesylate treatment on PDGFR-β, c-Kit, PDGF-BB and SCF protein expression related to untreated cell lines.](/cms/asset/3a63f836-c007-4b15-a32c-1071e6f7655b/dddt_a_124102_f0009_c.jpg)